The Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE. We asked, How are ocular toxicities associated with belantamab mafodotin managed in MM?
In this interview, Einsele discusses the proposed mechanism of belantamab mafodotin-associated ocular toxicity, strategies for monitoring ocular changes, and the role of dose modifications in managing ocular adverse events in patients with multiple myeloma.
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}